Daiichi won approval for Turalio on the strength of a 120-patient study that reported response rates of 39% for the study ...

LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

Daiichi Sankyo will seek to maintain its edge over competitors in precision cancer therapies by pushing ahead with clinical trials of drug candidates being developed using new technology ...

Daiichi Sankyo has been granted breakthrough status by the FDA for patritumab deruxtecan, a HER3-targeted antibody-drug conjugate (ADC) in clinical trials for lung cancer. The designation ...

Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the ...

Datopotamab deruxtecan is a specifically engineered TROP2-directed DXd antibody drug conjugate discovered by Daiichi Sankyo and being jointly developed by AstraZeneca and Daiichi Sankyo. AstraZeneca ...

The drug, developed with Japan's Daiichi Sankyo, showed an improvement in progression-free survival and overall survival in certain cancer patients regardless of their hormone receptor status.

Japan's Daiichi Sankyo has claimed its first worldwide approval ... 2 trial which revealed a 48% overall response rate with the drug in previously-treated ATL patients. ATL is a rare and highly ...

As one of the leading Japanese pharmaceutical companies with headquarters in Europe, Daiichi Sankyo aims to revolutionize treatment standards. Daiichi Sankyo, a pharmaceutical group boasting over ...

DS was established from the merger of Daiichi Pharmaceutical and Sankyo in 2005. As of 2021, we estimate over 60% of DS’ revenue comes from lucrative business lines, such as pain medication ...

The campaign is presented by Daiichi-Sankyo and AstraZeneca ... In addition to informing viewers about the drug itself, Dan Switzer, head of Daiichi’s U.S. oncology business, recently told ...